References
Key articles
Gómez RM, Jaquenod de Giusti C, Sanchez Vallduvi MM, et al. Junín virus. A XXI century update. Microbes Infect. 2011;13:303-311. Abstract
Enria DA, Briggiler AM, Sánchez Z. Treatment of Argentine hemorrhagic fever. Antiviral Res. 2008;78:132-9.Full text Abstract
Centers for Disease Control and Prevention. National notifiable diseases surveillance system (NNDSS). Viral hemorrhagic fever (VHF) 2025 case definition. 2024 [internet publication].Full text
Reference articles
1. Centers for Disease Control and Prevention. Viral hemorrhagic fevers (VHFs): about viral hemorrhagic fevers. Apr 2024 [internet publication].Full text
2. Patterson M, Grant A, Paessler S. Epidemiology and pathogenesis of Bolivian hemorrhagic fever. Curr Opin Virol. 2014;5:82-90.Full text Abstract
3. Gómez RM, Jaquenod de Giusti C, Sanchez Vallduvi MM, et al. Junín virus. A XXI century update. Microbes Infect. 2011;13:303-311. Abstract
4. Enria DA, Briggiler AM, Sánchez Z. Treatment of Argentine hemorrhagic fever. Antiviral Res. 2008;78:132-9.Full text Abstract
5. Enria DA, Briggiler AM, Feuillade MR. An overview of the epidemiological, ecological and preventive hallmarks of Argentine haemorrhagic fever (Junin virus). Bulletin Institut Pasteur. 1998;96:103-114.
6. de Manzione N, Salas RA, Paredes H, et al. Venezuelan hemorrhagic fever: clinical and epidemiological studies of 165 cases. Clin Infect Dis. 1998;26:308-13.Full text Abstract
7. Centers for Disease Control and Prevention. National notifiable diseases surveillance system (NNDSS). Viral hemorrhagic fever (VHF) 2025 case definition. 2024 [internet publication].Full text
8. Delgado S, Erickson BR, Agudo R, et al. Chapare virus, a newly discovered arenavirus isolated from a fatal hemorrhagic fever case in Bolivia. PLoS Pathog. 2008;4:e1000047.Full text Abstract
9. Barry M, Russi M, Armstrong L, et al. Brief report: treatment of a laboratory-acquired Sabiá virus infection. N Engl J Med. 1995;333:294-296.Full text Abstract
10. Sarute N, Ross SR. New world arenavirus biology. Annu Rev Virol. 2017 Sep 29;4(1):141-58.Full text Abstract
11. Grant A, Seregin A, Huang C, et al. Junín virus pathogenesis and virus replication. Viruses. 2012;4:2317-2339.Full text Abstract
12. PARODI AS, GREENWAY DJ, RUGIERO HR, et al. [Concerning the epidemic outbreak in Junin]. [in spa]. Dia Med. 1958 Sep 4;30(62):2300-1.
13. Salas R, de Manzione N, Tesh RB, et al. Venezuelan haemorrhagic fever. Lancet. 1991 Oct 26;338(8774):1033-6. Abstract
14. Johnson KM. Epidemiology of Machupo virus infection. 3. Significance of virological observations in man and animals. Am J Trop Med Hyg. 1965 Sep;14(5):816-8.
15. Lisieux T, Coimbra M, Nassar ES, et al. New arenavirus isolated in Brazil. Lancet. 1994 Feb 12;343(8894):391-2.Full text Abstract
16. Mackenzie RB. Epidemiology of Machupo virus infection. I. Pattern of human infection, San Joaquín, Bolivia, 1962-1964. Am J Trop Med Hyg. 1965;14:808-813. Abstract
17. Escalera-Antezana JP, Rodriguez-Villena OJ, Arancibia-Alba AW, et al. Clinical features of fatal cases of Chapare virus hemorrhagic fever originating from rural La Paz, Bolivia, 2019: A cluster analysis. Travel Med Infect Dis. 2020 Jul - Aug;36:101589. Abstract
18. University of Michigan; Animal diversity web. Browse animalia [internet publication].Full text
19. Fulhorst CF, Bowen MD, Salas RA, et al. Natural rodent host associations of Guanarito and pirital viruses (Family Arenaviridae) in central Venezuela. Am J Trop Med Hyg. 1999;61:325-330.Full text Abstract
20. Loayza Mafayle R, Morales-Betoulle ME, Romero C, et al. Chapare hemorrhagic fever and virus detection in rodents in Bolivia in 2019. N Engl J Med. 2022 Jun 16;386(24):2283-94.Full text Abstract
21. Abraham J, Corbett KD, Farzan M, et al. Structural basis for receptor recognition by New World hemorrhagic fever arenaviruses. Nat Struct Mol Biol. 2010;17:438-444.Full text Abstract
22. Zinzula L, Tramontano E. Strategies of highly pathogenic RNA viruses to block dsRNA detection by RIG-I-like receptors: hide, mask, hit. Antiviral Res. 2013;100:615-635. Abstract
23. Xing J, Ly H, Liang Y. The Z proteins of pathogenic but not nonpathogenic arenaviruses inhibit RIG-I-like receptor-dependent interferon production. J Virol. 2015;89:2944-2955.Full text Abstract
24. Fan L, Briese T, Lipkin WI. Z proteins of new world arenaviruses bind RIG-I and interfere with type I interferon induction. J Virol. 2010;84:1785-1791.Full text Abstract
25. Marta RF, Montero VS, Hack CE, et al. Proinflammatory cytokines and elastase-alpha-1-antitrypsin in Argentine hemorrhagic fever. Am J Trop Med Hyg. 1999;60:85-89.Full text Abstract
26. World Health Organization. Guidance: steps to remove personal protective equipment. 2014 [internet publication].Full text
27. Centers for Disease Control and Prevention. Guidance on personal protective equipment (PPE) to be used by healthcare workers during management of patients with confirmed Ebola or persons under investigation (PUIs) for Ebola who are clinically unstable or have bleeding, vomiting, or diarrhea in US hospitals, including procedures for donning and doffing PPE. August 2018 [internet publication].Full text
28. Olschläger S, Flatz L. Vaccination strategies against highly pathogenic arenaviruses: the next steps toward clinical trials. PLoS Pathog. 2013;9:e1003212.Full text Abstract
29. Kerber R, Reindl S, Romanowski V, et al. Research efforts to control highly pathogenic arenaviruses: a summary of the progress and gaps. J Clin Virol. 2015;64:120-127. Abstract
30. Health Protection Surveillance Centre. Laboratory diagnosis of viral haemorrhagic fever viruses. Dec 2022 [internet publication].Full text
31. Leligdowicz A, Fischer WA 2nd, Uyeki TM, et al. Ebola virus disease and critical illness. Crit Care. 2016;20:217. Abstract
32. Centers for Disease Control and Prevention. CDC Yellow Book 2024: health information for international travel. Section 5: viral hemorrhagic fevers. May 2023 [internet publication].Full text
33. Salam AP, Duvignaud A, Jaspard M, et al. Ribavirin for treating Lassa fever: a systematic review of pre-clinical studies and implications for human dosing. PLoS Negl Trop Dis. 2022 Mar;16(3):e0010289.Full text Abstract
34. Enria D, Mills JN, Bausch D, et al. Arenavirus infections. In: Guerrant RL, Walker DH, Weller PF, eds. Tropical infectious diseases: principles, pathogens, and practice. 3rd ed. Amsterdam: Elsevier; 2011:449-461.
35. Mcleod CG, Stookey JL, Eddy GA, et al. Pathology of chronic Bolivian hemorrhagic fever in the rhesus monkey. Am J Pathol. 1976 Aug;84(2):211-24.Full text Abstract
36. Salazar M, Yun NE, Poussard AL, et al. Effect of ribavirin on Junin virus infection in guinea pigs. Zoonoses Public Health. 2012;59:278-285. Abstract
37. Kilgore PE, Ksiazek TG, Rollin PE, et al. Treatment of Bolivian hemorrhagic fever with intravenous ribavirin. Clin Infect Dis. 1997;24:718-722.Full text Abstract
38. Mendenhall M, Russell A, Juelich T, et al. T-705 (favipiravir) inhibition of arenavirus replication in cell culture. Antimicrob Agents Chemother. 2011;55:782-7.Full text Abstract
39. Gowen BB, Juelich TL, Sefing EJ, et al. Favipiravir (T-705) inhibits Junín virus infection and reduces mortality in a guinea pig model of Argentine hemorrhagic fever. PLoS Negl Trop Dis. 2013;7:e2614.Full text Abstract
40. Sissoko D, Laouenan C, Folkesson E, et al. Experimental treatment with favipiravir for Ebola virus disease (the JIKI trial): a historically controlled, single-arm proof-of-concept trial in Guinea. PLoS Med. 2016;13:e1001967.Full text Abstract
41. Rosenke K, Feldmann H, Westover JB, et al. Use of favipiravir to treat lassa virus infection in Macaques. Emerg Infect Dis. 2018 Sep;24(9):1696-9.Full text Abstract
42. Veliziotis I, Roman A, Martiny D, et al. Clinical management of Argentine hemorrhagic gever using ribavirin and favipiravir, Belgium, 2020. Emerg Infect Dis. 2020 Jul;26(7):1562-6.Full text Abstract
43. Lavanya M, Cuevas CD, Thomas M, et al. siRNA screen for genes that affect Junín virus entry uncovers voltage-gated calcium channels as a therapeutic target. Sci Transl Med. 2013;5:204ra131.Full text Abstract
44. Amanat F, Duehr J, Huang C, et al. Monoclonal antibodies with neutralizing activity and Fc-effector functions against the Machupo virus glycoprotein. J Virol. 2020 Feb 14;94(5):e01741-19.Full text Abstract
45. Pan X, Wu Y, Wang W, et al. Novel neutralizing monoclonal antibodies against Junin virus. Antiviral Res. 2018 Aug;156:21-8. Abstract
46. Zeitlin L, Geisbert JB, Deer DJ, et al. Monoclonal antibody therapy for Junin virus infection. Proc Natl Acad Sci U S A. 2016 Apr 19;113(16):4458-63.Full text Abstract
47. Zeitlin L, Cross RW, Geisbert JB, et al. Therapy for Argentine hemorrhagic fever in nonhuman primates with a humanized monoclonal antibody. Proc Natl Acad Sci U S A. 2021 Mar 16;118(11):e2023332118.Full text Abstract
48. Mapp Biopharmaceutical. LeafBio announces conclusion of ZMapp™ clinical trial. February 2016 [internet publication].Full text
49. Kolokoltsova OA, Yun NE, Paessler S. Reactive astrogliosis in response to hemorrhagic fever virus: microarray profile of Junin virus-infected human astrocytes. Virol J. 2014;11:126.Full text Abstract
50. McLay L, Liang Y, Ly H. Comparative analysis of disease pathogenesis and molecular mechanisms of New World and Old World arenavirus infections. J Gen Virol. 2014;95:1-15.Full text Abstract
51. Enría DA, Damilano AJ, Briggiler AM, et al. Sindrome neurologico tardio en enfermos de fiebre hemorrágica Argentina tratados con plasma immune. Medicina (Buenos Aires). 1985;45:615-620.
52. Melcon MO, Herskovits E. Complicaciones neurologicas tardias de la fiebre hemorragica argentina. Medicina (Buenos Aires). 1981;41:137-145.
53. Briggiler AM, Enria DA, Feuillade MR, et al. Contagio interhumano e infeccion inaparente por virus Junin in matrimonios del area endemica de fiebre hemorragica Argentina. Medicina (Buenos Aires). 1987;47:565.
54. Maiztegui JI, Fernandez NJ, de Damilano AJ. Efficacy of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and a late neurological syndrome. Lancet. 1979;2:1216-1217. Abstract
Use of this content is subject to our disclaimer